-
Company Insights
Innovation and Patenting activity of OVS SpA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of OVS SpA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OV-329 in Partial Seizure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OV-329 in Partial Seizure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OV-329 in Partial Seizure Drug Details: Small molecule is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OV-329 in Tuberous Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OV-329 in Tuberous Sclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OV-329 in Tuberous Sclerosis Drug Details: Small molecule is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soticlestat in Lennox-Gastaut Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Soticlestat in Lennox-Gastaut Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Soticlestat in Lennox-Gastaut Syndrome Drug Details: Soticlestat (TAK-935, OV-935) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soticlestat in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Soticlestat in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Soticlestat in Dravet Syndrome (Severe Myoclonic Epilepsy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OV-329 in Infantile Spasm (West Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OV-329 in Infantile Spasm (West Syndrome) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OV-329 in Infantile Spasm (West Syndrome) Drug Details: Small...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cetuximab Biobetter in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab Biobetter in Nasopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cetuximab Biobetter in Nasopharyngeal Cancer Drug Details: HLX-07 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soticlestat in Lennox-Gastaut Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Soticlestat in Lennox-Gastaut Syndrome Drug Details: Soticlestat (TAK-935, OV-935) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soticlestat in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Soticlestat in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Drug Details: Soticlestat (TAK-935, OV-935) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soticlestat in Tuberous Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Soticlestat in Tuberous Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Soticlestat in Tuberous SclerosisDrug Details:Soticlestat (TAK-935, OV-935) is under development for the treatment...